Patients with CalR mutation – promising ASH update
The American Society of Hematology’s December 2024 conference included developments in treatments for MPN patients with the CalR mutation. A range of Australian and international immunotherapy research is underway and some treatments are already in clinical trials. It is too early to present results.
A fascinating video about CalR treatment research is linked below.
In the video, Drs Alex Rampotas and Zoë Wong explain that there are already specific immunotherapies being trialled against the CalR mutation, all of which may well be effective. They specifically mention a ‘B specific T cell engager’ and ‘a blocking antibody against it’.
However their collaboration is about a third type of immunotherapy option, a novel second generation CAR-T cell therapy. They advise that CAR-T is the ‘strongest immunotherapy so potentially ……. able to overcome some of the immune suppression of myelofibrosis and directly eliminate the malignant stell cells.’
The full video is 8 minutes long, unfortunately with background noise. However if you have the CalR mutation, watching the video will give you a Christmas present of great promise!
